The frequency of innate anomalies throughout the world varies and to a greater extent depends on the surveillance system management. The prevention of foetal congenital anomalies during preconception, prenatal and postnatal stages is a top-priority target of the health care service. Analysing the pharmacotherapy of 1306 pregnant women in Primorsky Krai in 2004-2010, the authors concluded that the medications were being prescribed during the first and the second critical periods. Only 27.94 % of prescribed medications were relatively safe for foetus (А, В FDA categories). In 36.12 % of cases these were drugs of unascertained safety (N FDA category). In 35.94 % cases the doctors prescribed medications known for their risks for teratogenic and embryotoxic properties (C, D, X FDA categories). As reported, the joint efforts of genetics and clinical pharmacologists allow to increase the safety in prescribing medications for pregnant women.